Danish healthcare firm pledges millions in fight against urban diabetes

16 November 2015

Danish diabetes care giant Novo Nordisk (NOV: N) has pledged $20 million towards the fight against urban diabetes following pioneering research by University College London (UCL).

An international study, commissioned by the Cities Changing Diabetes Partnership and led by UCL, revealed that social, cultural and economic factors play a far greater role in the spread of urban diabetes than previously thought.

Researchers found that diabetes vulnerability in cities is linked to financial and geographical factors as well as resource and time constraints. Cultural determinants included the perception of body size and health.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK